Franklin Resources Inc Vir Biotechnology, Inc. Transaction History

Franklin Resources Inc

  • $334 Billion
  • Q3 2024

A detailed history of Franklin Resources Inc transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Franklin Resources Inc holds 97,948 shares of VIR stock, worth $722,856. This represents 0.0% of its overall portfolio holdings.

Number of Shares
97,948
Previous 97,948 -0.0%
Holding current value
$722,856
Previous $733,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$7.26 - $10.7 $16,211 - $23,893
-2,233 Reduced 2.23%
97,948 $733,000
Q2 2024

Aug 14, 2024
SELL
$7.63 - $12.66 $20,700 - $34,346
-2,713 Reduced 2.64%
100,181 $891,000
Q1 2024

May 13, 2024
BUY
$8.6 - $11.9 $757,273 - $1.05 Million
88,055 Added 593.4%
102,894 $1.04 Million
Q4 2023

Feb 09, 2024
SELL
$7.76 - $10.29 $7,255 - $9,621
-935 Reduced 5.93%
14,839 $149,000
Q3 2023

Nov 13, 2023
SELL
$9.14 - $24.62 $132,593 - $357,162
-14,507 Reduced 47.91%
15,774 $147,000
Q2 2023

Aug 11, 2023
BUY
$23.2 - $27.29 $420,662 - $494,822
18,132 Added 149.25%
30,281 $742,000
Q1 2023

May 12, 2023
BUY
$22.26 - $30.85 $48,192 - $66,790
2,165 Added 21.68%
12,149 $282,000
Q4 2022

Feb 10, 2023
BUY
$19.96 - $28.22 $199,280 - $281,748
9,984 New
9,984 $252,000
Q2 2022

Aug 11, 2022
SELL
$19.08 - $26.7 $61,055 - $85,440
-3,200 Reduced 25.74%
9,230 $235,000
Q1 2022

May 13, 2022
SELL
$21.19 - $40.01 $4,873 - $9,202
-230 Reduced 1.82%
12,430 $320,000
Q4 2021

Feb 11, 2022
BUY
$30.97 - $54.03 $392,080 - $684,019
12,660 New
12,660 $530,000

Others Institutions Holding VIR

# of Institutions
218
Shares Held
87M
Call Options Held
127K
Put Options Held
1.19M
View Full List

About Vir Biotechnology, Inc.

VIR Quotes by TradingView
  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $979M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Franklin Resources Inc Portfolio

Follow Franklin Resources Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email